Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Fortrea Holdings Inc.

Healthcare US FTRE

8.95USD
-0.88(8.95%)

Last update at 2026-03-10T20:28:00Z

Day Range

8.729.91
LowHigh

52 Week Range

24.9341.02
LowHigh

Fundamentals

  • Previous Close 9.83
  • Market Cap2252.22M
  • Volume2903077
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA136.00M
  • Revenue TTM3077.20M
  • Revenue Per Share TTM34.61
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax 58.90M 136.40M -332.20000M
Minority interest - - -
Net income 58.40M 98.00M -359.20000M
Selling general administrative 299.90M 303.10M 267.60M
Selling and marketing expenses - - -
Gross profit 621.70M 604.40M 489.10M
Reconciled depreciation 92.70M 166.30M 119.00M
Ebit 236.10M 135.50M 538.00M
Ebitda 328.80M 301.80M 657.00M
Depreciation and amortization 92.70M 166.30M 119.00M
Non operating income net other - - -
Operating income 185.20M 114.30M -314.20000M
Other operating expenses 2870.60M 2922.50M 2477.80M
Interest expense 132.40M - -
Tax provision 0.50M 38.40M 27.00M
Interest income - - -
Net interest income -132.40000M - -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 0.50M 38.40M 27.00M
Total revenue 3096.10M 3057.50M 2580.30M
Total operating expenses 396.20M 469.40M 386.60M
Cost of revenue 2474.40M 2453.10M 2091.20M
Total other income expense net -34.20000M 1.40M -434.70000M
Discontinued operations - - -
Net income from continuing ops 58.40M 98.00M -359.20000M
Net income applicable to common shares - - -
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 4357.20M 4287.90M 4368.70M -
Intangible assets 771.20M 823.30M 935.50M -
Earning assets - - - -
Other current assets 35.10M 83.50M 73.10M -
Total liab 2618.40M 945.30M 1108.10M -
Total stockholder equity 1738.80M 3342.60M 3260.60M -
Deferred long term liab - - - -
Other current liab 356.10M 322.70M 435.20M -
Common stock 0.10M - - -
Capital stock 0.10M - - -
Retained earnings -49.10000M - - -
Other liab - - - -
Good will 2029.30M 1997.30M 2080.90M -
Other assets - - - -
Cash 108.60M 112.00M 94.60M -
Cash and equivalents - - - -
Total current liabilities 775.90M 699.00M 826.70M -
Current deferred revenue 241.40M 271.50M 307.00M -
Net debt 1569.40M -48.60000M -17.40000M -
Short term debt 45.60M 23.30M 24.00M -
Short long term debt 26.10M - - -
Short long term debt total 1678.00M 63.40M 77.20M -
Other stockholder equity 2006.20M 3618.60M 3409.00M -
Property plant equipment - - - -
Total current assets 1253.10M 1246.90M 1117.50M -
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables 1074.10M 1051.40M 949.80M -
Long term debt 1565.90M - - -
Inventory 35.30M - - -
Accounts payable 132.80M 81.50M 60.50M -
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -218.40000M -276.00000M -148.40000M -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 79.50M 54.30M 70.80M -
Deferred long term asset charges - - - -
Non current assets total 3104.10M 3041.00M 3251.20M -
Capital lease obligations 86.00M 63.40M 77.20M -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -54.00000M -26.20000M -161.20000M
Change to liabilities - - -
Total cashflows from investing activities - - -
Net borrowings - - -
Total cash from financing activities -8.70000M -128.50000M -33.10000M
Change to operating activities - - -
Net income 192.90M 98.00M -359.20000M
Change in cash 17.40M 14.30M 7.10M
Begin period cash flow 94.60M 80.30M 73.20M
End period cash flow 112.00M 94.60M 80.30M
Total cash from operating activities 87.50M 169.80M 200.90M
Issuance of capital stock - - -
Depreciation 92.70M 166.30M 119.00M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities -8.70000M -128.50000M -33.10000M
Change to netincome - - -
Capital expenditures 54.40M 26.50M 24.00M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital -245.80000M -127.20000M 8.90M
Stock based compensation 25.40M 27.50M 23.10M
Other non cash items 38.80M 35.40M 449.40M
Free cash flow 33.10M 143.30M 176.90M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
FTRE
Fortrea Holdings Inc.		 -0.88 8.95% 8.95 - - - -
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Fortrea Holdings Inc.

8 Moore Drive, Durham, NC, United States, 27709

Key Executives

Name Title Year Born
Mr. Thomas H. Pike CEO, President & Chairman 1959
Ms. Jill McConnell Chief Financial Officer 1975
Mr. Mark A. Morais COO & President of Clinical Services 1977
Amanda M. Warren Chief Accounting Officer NA
Ms. Hima B. Inguva Head of Investor Relations & Corporate Development NA
Stillman Hanson General Counsel & Corporate Secretary NA
Dr. John J. Doyle President of Consulting NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.